TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8871751

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (300 IU/kg)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study: 1502021

Group type: EXPERIMENTAL
Intervention: Ticlopidine (500 mg/day) for 24 weeks
Number of subjects: 615

Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 615
Study: 6383692

Group type: EXPERIMENTAL
Intervention: High-dose naloxone infusion during severe exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline infusion during severe exercise
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Exercise (both mild and severe)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Naloxone infusion
Number of subjects: 6
Study: 31674256

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment (CT) group with low-dose dexamethasone (5mg/d) for 5 days
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment (CT) group
Number of subjects: 121

Group type: COMPARATOR
Intervention: Medical comprehensive treatment (MCT) group
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 121
Study: 30071781

Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation (10.6 µm)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control non-therapeutic light
Number of subjects: 26
Study: 27451942

Group type: EXPERIMENTAL
Intervention: ESAT6‐CFP10 (0.1, 0.5, 1 or 2 μg)
Number of subjects: 144

Group type: COMPARATOR
Intervention: TB‐PPD
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: ESAT6‐CFP10
Number of subjects: 144
Study: 24666527

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: SSRIs and Placebo
Number of subjects: 72
Study: 22875822

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 704
Study: 18503492

Group type: EXPERIMENTAL
Intervention: Combined weight‐bearing program
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 34
Study: 17687925

Group type: EXPERIMENTAL
Intervention: VEGF inhibitors (pegaptanib, ranibizumab, bevacizumab)
Number of subjects: 0
Study: 15158629

Group type: EXPERIMENTAL
Intervention: Elemental zinc (20 mg per day)
Number of subjects: 270
Study: 11673813

Group type: EXPERIMENTAL
Intervention: Remune monotherapy (administered every 12 weeks)
Number of subjects: 223
Study: 9040630

Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium solution (30% dextrose in water; K+, 80 mEq/L; regular insulin, 50 units) given intravenously at 1 ml/kg per hour for 12 hours after aortic unclamping
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium solution
Number of subjects: 30

Group type: COMPARATOR
Intervention: 5% dextrose in water (control)
Number of subjects: 30
Study: 7702278

Group type: EXPERIMENTAL
Intervention: Topical tretinoin applied twice daily for 4 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo applied twice daily for 4 months
Number of subjects: 40
Study: 3584748

Group type: EXPERIMENTAL
Intervention: Clonidine (75 micrograms, two doses)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29405635

Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg twice daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Metformin (in healthy controls)
Number of subjects: 36
Study: 27622565

Group type: EXPERIMENTAL
Intervention: Dual-energy computed tomography coronary angiography (DE-CTCA) at 45 keV
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Dual-energy computed tomography coronary angiography (DE-CTCA) at 65 keV
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Dual-energy computed tomography coronary angiography (DE-CTCA) at 85 keV
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Dual-energy computed tomography coronary angiography (DE-CTCA) at 45 keV with moderate calcification
Number of subjects: 67
Study: 24618012

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (walking trial)
Number of subjects: 328
Study: 23230756

Group type: EXPERIMENTAL
Intervention: Topical application of autologous platelet-rich gel (APG)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 117
Study: 20608820

Group type: EXPERIMENTAL
Intervention: Intraosseous epinephrine administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard epinephrine administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basic life support measures (chest compressions, defibrillation, postresuscitation care)
Number of subjects: 0
Study: 18296456

Group type: EXPERIMENTAL
Intervention: Induced hypocrisy intervention
Number of subjects: 0
Study: 15973948

Group type: EXPERIMENTAL
Intervention: Beta-tricalcium phosphate (Cerasorb)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Autogenous bone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Comparison of both grafts
Number of subjects: 20
Study: 12745511

Group type: EXPERIMENTAL
Intervention: 300mg bupropion SR + placebo patch
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: 300mg bupropion SR + 21 mg/24-hr nicotine patch
Number of subjects: 893

Group type: COMPARATOR
Intervention: 21 mg/24-hr nicotine patch
Number of subjects: 893

Group type: COMPARATOR
Intervention: placebo tablet + placebo patch
Number of subjects: 893

Group type: COMPARATOR
Intervention: placebo tablet + 21 mg/24-hr nicotine patch
Number of subjects: 893
Study: 12504657

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) 10 mg/m2 on day 1 and continuous infusion of 5-fluorouracil (5-FU) 200 mg/m2 from days 1-26 in the first sequence (36 Gy over 4 weeks) and 5-FU 200 mg/m2 from days 1-17 in the second sequence (23.4 Gy over 17 days)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) 10 mg/m2 on day 1 and continuous infusion of 5-fluorouracil (5-FU) 200 mg/m2
Number of subjects: 43
Study: 10701483

Group type: EXPERIMENTAL
Intervention: Idazoxan, titrated to 240 mg/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bupropion, titrated to 450 mg/day
Number of subjects: 14
Study: 7786531

Group type: EXPERIMENTAL
Intervention: Propafenone 300 mg twice daily
Number of subjects: 207

Group type: COMPARATOR
Intervention: Atenolol 50 mg once daily
Number of subjects: 207
Study: 2190840

Group type: EXPERIMENTAL
Intervention: Silver alloy and hydrogel-coated Foley catheter (SHC)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hydrogel-coated catheter (HC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Non-coated catheter (NC)
Number of subjects: 90
Study: 27977068

Group type: EXPERIMENTAL
Intervention: Therapist delivered interventions for low back pain (specific interventions not detailed in the abstract)
Number of subjects: 9328
Study: 25496433

Group type: EXPERIMENTAL
Intervention: Goal management training (GMT) for 21 hours
Number of subjects: 38

Group type: COMPARATOR
Intervention: Wait-list condition (control)
Number of subjects: 38
Study: 24386664

Group type: EXPERIMENTAL
Intervention: Brivaracetam 400 mg/day
Number of subjects: 24
Study: 20392617

Group type: EXPERIMENTAL
Intervention: 1 portion of fruit and vegetable (FV) daily for 8 weeks
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 3 portions of fruit and vegetable (FV) daily for 8 weeks
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 6 portions of fruit and vegetable (FV) daily for 8 weeks
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Increased FV consumption
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (1 portion of FV daily during run-in period)
Number of subjects: 117
Study: 19346113

Group type: EXPERIMENTAL
Intervention: 25g/d of sesame (approximately 50mg/d of sesame lignan)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Iso-caloric placebo matched for macronutrient composition
Number of subjects: 33
Study: 17130849

Group type: EXPERIMENTAL
Intervention: 2.5 mg lidocaine per nostril
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10 mg lidocaine per nostril
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 25 mg lidocaine per nostril
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 20
Study: 15101566

Group type: EXPERIMENTAL
Intervention: Sulpiride augmentation (600 mg/day) with olanzapine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Olanzapine monotherapy (control group)
Number of subjects: 17
Study: 11339914

Group type: EXPERIMENTAL
Intervention: 12 sessions of pelvic floor exercises with biofeedback and electrostimulation (n = 51)
Number of subjects: 107

Group type: COMPARATOR
Intervention: No training (n = 56)
Number of subjects: 107
Study: 9090591

Group type: EXPERIMENTAL
Intervention: RARE (rapid acquisition with relaxation enhancement)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: FLASH (fast low‐angle shot)
Number of subjects: 7
Study: 7525169

Group type: EXPERIMENTAL
Intervention: Interferon therapy
Number of subjects: 18
Study: 2439854

Group type: EXPERIMENTAL
Intervention: Endoscopic stent insertion
Number of subjects: 75

Group type: COMPARATOR
Intervention: Percutaneous stent insertion
Number of subjects: 75
Study: 31818823

Group type: EXPERIMENTAL
Intervention: Gepotidacin 750 mg every 12 hours (q12h)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Gepotidacin 1,000 mg every 12 hours (q12h)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Gepotidacin 1,000 mg every 8 hours (q8h)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Gepotidacin (all doses)
Number of subjects: 102
Study: 30431387

Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib
Number of subjects: 100

Group type: COMPARATOR
Intervention: DTPa-IPV+Hib
Number of subjects: 100
Study: 25415413

Group type: EXPERIMENTAL
Intervention: Foam rolling (20 minutes immediately, 24, and 48 hours post-exercise)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Foam rolling
Number of subjects: 8

Group type: COMPARATOR
Intervention: No foam rolling (control)
Number of subjects: 8
Study: 24267040

Group type: EXPERIMENTAL
Intervention: Walnut-enriched meal
Number of subjects: 21

Group type: COMPARATOR
Intervention: Butter-enriched meal
Number of subjects: 21

Group type: COMPARATOR
Intervention: Olive oil-enriched meal
Number of subjects: 21
Study: 21843716

Group type: EXPERIMENTAL
Intervention: Fundoplication at hernia repair
Number of subjects: 79

Group type: COMPARATOR
Intervention: Regular hernia closure
Number of subjects: 79
Study: 19281877

Group type: EXPERIMENTAL
Intervention: Hospitalization for surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Newly diagnosed patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Clinically treated patients
Number of subjects: 30
Study: 17577103

Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg BID
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Duloxetine 200 mg BID
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Duloxetine 160 mg BID
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Duloxetine (various dosages)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Duloxetine (supratherapeutic dosages)
Number of subjects: 117
Study: 15701933

Group type: EXPERIMENTAL
Intervention: Intensive practice-based parenting programme
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 42
Study: 11154253

Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention including a series of simple exercises and repositioning of the kneecap using tape.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention
Number of subjects: 20
Study: 9522134

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (50 mg) intra‐articular (IA)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 1 mg of 0.1% preservative free morphine chloride in saline
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 1 mg of 0.1% preservative free morphine chloride in 0.25% bupivacaine
Number of subjects: 103

Group type: COMPARATOR
Intervention: Normal saline (0.9%)
Number of subjects: 103
Study: 7855606

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis for postoperative infections
Number of subjects: 32

Group type: COMPARATOR
Intervention: Patients with superficial wound infection
Number of subjects: 32

Group type: COMPARATOR
Intervention: Patients with deep wound infection
Number of subjects: 32
Study: 2478604

Group type: EXPERIMENTAL
Intervention: 10 or 100 times the concentration of allergen required for 4+ early intradermal reaction
Number of subjects: 24

Group type: COMPARATOR
Intervention: Diluent
Number of subjects: 24
Study: 799983

Group type: EXPERIMENTAL
Intervention: Betamethasone-17, 21-dipropionate and salicylic acid treatment
Number of subjects: 0
Study: 31502392

Group type: EXPERIMENTAL
Intervention: 30% metformin lotion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Triple combination cream (TCC) (hydroquinone 2% + tretinoin 0.025% + fluocinolone acetonide 0.01%)
Number of subjects: 40
Study: 31605113

Group type: EXPERIMENTAL
Intervention: RSV/ΔNS2/Δ1313/I1314L vaccine at 106 PFU
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: RSV/ΔNS2/Δ1313/I1314L vaccine at 105 PFU
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 27756788

Group type: EXPERIMENTAL
Intervention: Urelumab 0.1 mg/kg every 3 weeks
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Urelumab doses between 1 and 15 mg/kg every 3 weeks
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Urelumab doses ≥1 mg/kg
Number of subjects: 346
Study: 25103549

Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Number of subjects: 120

Group type: COMPARATOR
Intervention: Octreotide LAR
Number of subjects: 120
Study: 24283127

Group type: EXPERIMENTAL
Intervention: Gel beads containing Eimeria oocysts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spray vaccination with Eimeria oocysts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gel beads or spray vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: All immunized groups
Number of subjects: 0
Study: 21487215

Group type: EXPERIMENTAL
Intervention: Breastfed infants (BF)
Number of subjects: 1678

Group type: EXPERIMENTAL
Intervention: Formula-fed infants (FF)
Number of subjects: 1678

Group type: COMPARATOR
Intervention: Comparison between BF and FF infants
Number of subjects: 1678

Group type: COMPARATOR
Intervention: Timing of introduction of potentially allergenic foods
Number of subjects: 1678
Study: 18029002

Group type: EXPERIMENTAL
Intervention: Concealed question interpretation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Critical verbs presented in isolation
Number of subjects: 0
Study: 16751153

Group type: EXPERIMENTAL
Intervention: Detemir
Number of subjects: 0
Study: 12742981

Group type: EXPERIMENTAL
Intervention: VEGF adenovirus (VEGF‐Adv, 2x10(10) pfu)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: VEGF plasmid liposome (VEGF‐P/L; 2000 microg of DNA with 2000 microL of DOTMA:DOPE [1:1 wt/wt])
Number of subjects: 103

Group type: COMPARATOR
Intervention: Ringer's lactate (Control)
Number of subjects: 103
Study: 10694896

Group type: EXPERIMENTAL
Intervention: 5-isosorbide mononitrate (ISMO) 20 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 11322264

Group type: EXPERIMENTAL
Intervention: Hydroxyurea plus didanosine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Hydroxyurea plus zidovudine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Hydroxyurea monotherapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Zidovudine monotherapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Didanosine monotherapy
Number of subjects: 29
Study: 8385040

Group type: EXPERIMENTAL
Intervention: Psyllium
Number of subjects: 9

Group type: COMPARATOR
Intervention: Calcium polycarbophil
Number of subjects: 9

Group type: COMPARATOR
Intervention: Wheat bran
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 3699924

Group type: EXPERIMENTAL
Intervention: Group A (went up by train/road transport to 3658 m)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Group B (reached the same height after 8 days of acclimatisation en route)
Number of subjects: 50
Study: 30412360

Group type: EXPERIMENTAL
Intervention: D/C/F/TAF in fasted conditions
Number of subjects: 120

Group type: COMPARATOR
Intervention: D/C/F/TAF after a standardized high-fat breakfast
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: D/C/F/TAF
Number of subjects: 120
Study: 29524621

Group type: EXPERIMENTAL
Intervention: GHB (35 mg/kg p.o.)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 26344811

Group type: EXPERIMENTAL
Intervention: Emulsion preload containing 2 μm oil droplets
Number of subjects: 34

Group type: COMPARATOR
Intervention: Emulsion preload containing 50 μm oil droplets
Number of subjects: 34
Study: 24446590

Group type: EXPERIMENTAL
Intervention: Conventional gingival displacement (gingival cord + 25% AlCl3 astringent gel)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cordless gingival displacement (15% AlCl3 astringent-based paste)
Number of subjects: 12
Study: 22562021

Group type: EXPERIMENTAL
Intervention: Adalimumab high dose (40 mg or 20 mg for body weight >/=40 kg or <40 kg; n = 93)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Adalimumab low dose (20 mg or 10 mg for body weight >/=40 kg or <40 kg; n = 95)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (not specified, but implied as patients not receiving adalimumab)
Number of subjects: 192
Study: 20059776

Group type: EXPERIMENTAL
Intervention: Cardiovascular prevention program (medical interventions and optional behavior-change interventions)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 314
Study: 17617522

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (AC)
Number of subjects: 4626
Study: 15570084

Group type: EXPERIMENTAL
Intervention: Tipifarnib 100 mg bid
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tipifarnib 200 mg bid
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tipifarnib 300 mg bid
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tipifarnib 600 mg bid
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tipifarnib (all doses)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tipifarnib (responders)
Number of subjects: 42
Study: 11213010

Group type: EXPERIMENTAL
Intervention: 40 mg prednisolone daily in two divided oral doses
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 9625686

Group type: COMPARATOR
Intervention: Short technical reports
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Long clinical reports
Number of subjects: 57
Study: 8158537

Group type: EXPERIMENTAL
Intervention: B cells secreting IgG anti-gp160/120 antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serologic response in HIV-infected patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serologic response in gp160/gp120-immunized volunteers
Number of subjects: 0
Study: 3139387

Group type: EXPERIMENTAL
Intervention: Surgery and transfusion
Number of subjects: 1100

Group type: COMPARATOR
Intervention: No transfusion (with or without surgery)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Transfused group
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: All groups (including transfusion and surgery)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Overall incidence
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Silent hepatitis cases
Number of subjects: 1100
Study: 29617468

Group type: EXPERIMENTAL
Intervention: Use of snack bars or fast-food outlets
Number of subjects: 2195

Group type: EXPERIMENTAL
Intervention: Use of butchers
Number of subjects: 2195
Study: 28787504

Group type: EXPERIMENTAL
Intervention: Improvisational music therapy
Number of subjects: 364

Group type: COMPARATOR
Intervention: Enhanced standard care
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Exploratory secondary outcomes
Number of subjects: 364
Study: 26579561

Group type: EXPERIMENTAL
Intervention: Schema therapy
Number of subjects: 320

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Clarification‐oriented psychotherapy
Number of subjects: 320
Study: 24247643

Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Straw
Number of subjects: 42
Study: 21530253

Group type: EXPERIMENTAL
Intervention: Oncoplastic surgery
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conservative surgery without breast reconstruction (control group)
Number of subjects: 90
Study: 18979376

Group type: EXPERIMENTAL
Intervention: Dynamic body expressions of anger (videos)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Still body expressions of anger (stills)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral body expressions (stills/videos)
Number of subjects: 0
Study: 16798925

Group type: EXPERIMENTAL
Intervention: Medium screens (low tube potential setting)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Regular film-screen combinations (high tube potential settings)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Digital system (irrespective of exposure)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Digital system
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Intrarater agreement
Number of subjects: 201
Study: 12699507

Group type: EXPERIMENTAL
Intervention: Airway Pressure Release Ventilation (APRV)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Synchronized Intermittent Mandatory Ventilation with Pressure Support (SIMV-PC/PS)
Number of subjects: 33
Study: 10675054

Group type: EXPERIMENTAL
Intervention: Spanish-language version of the Health-Promoting Lifestyle Profile II
Number of subjects: 60
Study: 9509822

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 35
Study: 8465379

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 150

Group type: COMPARATOR
Intervention: No supplementation (Control)
Number of subjects: 150
Study: 4054138

Group type: EXPERIMENTAL
Intervention: PY-108-068 75 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: PY-108-068 150 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31390198

Group type: EXPERIMENTAL
Intervention: Systematic FCI-FRI scheme
Number of subjects: 5

Group type: COMPARATOR
Intervention: Multinomial FCI-FRI scheme
Number of subjects: 5

Group type: COMPARATOR
Intervention: Original FCIQMC algorithm
Number of subjects: 5